Wyeth

Addition of Fort Dodge Animal Health Products Diversifies and Enhances Pfizer’s Already Robust U.S. Portfolio

October 19, 2009 -- NEW YORK -- A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world’s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.    » read more »

October 15, 2009 -- NEW YORK -- Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a share of Pfizer common stock.

Effective as of the close of trading today, October 15, 2009, Wyeth common stock (NYSE: WYE) will cease trading.    » read more »

Announces Date for Annual Meeting of Stockholders; Stockholders to Vote on Merger Agreement with Pfizer

Madison, N.J., June 18, 2009 – Wyeth (NYSE:WYE) today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission for its Annual Meeting of Stockholders. Among other matters, stockholders will vote on Wyeth’s merger agreement with Pfizer (NYSE: PFE), which was announced on January 26, 2009.    » read more »

Drug Company Allegedly Failed to Pay Hundreds of Millions in Rebates to Medicaid Program

May 18, 2009 -- WASHINGTON – The United States and 16 states have joined in two whistleblower suits filed in the District of Massachusetts against the drug manufacturer, Wyeth, alleging that the company knowingly failed to give the government the same discounts it provided to private purchasers of its drugs, as required by laws governing the Medicaid program.

As a result, Wyeth allegedly avoided paying hundreds of millions in rebates due to state Medicaid programs for its drugs, Protonix Oral and Protonix IV. These drugs belong to a class of drugs known as proton pump inhibitors (PPI), which are used to suppress stomach acid.    » read more »